Spectrum Laboratory Products, Inc. is voluntarily recalling three lots of Epinephrine (L-Adrenaline) USP, a bulk active pharmaceutical ingredient (API) used to manufacture or compound prescription products, to the user level. Customer complaints have found the product to be discolored.
Similar Posts
Covalent Medical – 695839 – 07/09/2025
Unapproved New Drugs/MisbrandedPostmarketing Requirements and Commitments: Searchable Database
Learn more about FDA’s Postmarketing Requirements and Commitments Searchable Database.ICH M13B Webinar: Navigating the Draft ICH M13B Additional Strengths Biowaiver Guideline – 09/11/2025
This webinar will provide an in-depth look at the draft ICH M13B guideline titled “Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver” that was endorsed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Assembly in March 2025.CDER/Office of New Drugs Streamlined Nonclinical Studies and Acceptable New Approach Methodologies (NAMs)
It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.CDER Leadership Bios
CDER Leadership Bios